StockIQ.techSiemens Healthineers AG (SHL.DE) Stock Analysis
Free AI-powered analysis and research for Siemens Healthineers AG stock
Sector: Healthcare
SHL.DE snapshot
Data as of 4 Nov 2026 close. Updated daily.
Siemens Healthineers AG scores 63/100 on StockIQ's model, which reads as positive signals overall. The price is above its 200-day average and at 73% of its 52-week range, down 8.9% over the past year. Latest reported figures show a profit margin of 9.6%, return on equity of 12.1% and revenue growth of +1.8%.
What is driving the score
- RSI Very High (81): -5
- Strong Uptrend: +12
- MACD Bullish: +8
- Weak Liquidity (1.16 Current Ratio): -5
- Strong Long-term Uptrend: +8
- Underperforming (-8.9% over 1 year): -5
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full SHL.DE report
Siemens Healthineers AG (SHL.DE) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze SHL.DE Now →📰 Latest Update
TDM Reagent Kit Market Forecasts Growth from $2.87B (2026) to $6.96B by 2032, Profiling Abbott, Roche, Danaher, Siemens Healthineers & Thermo Fisher
Thu, September 24, 2026 at 12:59 PM UTC 3 min read
The TDM Reagent Kit market is projected to grow significantly from $2.87 billion in 2026 to $6.96 billion by 2032, highlighting a strong demand for therapeutic drug monitoring solutions. Key players in this market include Abbott, Roche, Danaher, Siemens Healthineers, and Thermo Fisher. This growth indicates potential opportunities for investors in companies involved in this sector, as increasing healthcare needs and advancements in diagnostics drive market expansion.